taksta taksta taksta (previously cem-102) is a front-loaded oral dosing regimen of sodium fusidate under development in the u.s. as an antibiotic for gram-positive infections including drug-resistant strains such as methicillin-resistant staphylococcus aureus (mrsa). clinical trials jan 2010: taksta has completed enrollment in a phase 2 trial (due to run until march 2010) and is preparing for phase 3 studies in the u.s. for acute bacterial skin structure infections (being compared with linezolid). sep 2010: taksta demonstrated comparable clinical success rates compared to linezolid in a phase 2 trial in the u.s. for acute bacterial skin and skin structure infections. jun 2011: taksta may be effective in the treatment of chronic prosthetic joint infections and osteomyelitis. dec 2015: cempra doses first patient in phase 3 clinical trial of taksta(tm) in acute bacterial skin and skin structure infections. (2015) nov 2016: cempra completes phase 3 clinical trial of taksta(tm) in acute bacterial skin and skin structure infections. results remain pending. (2016) feb 2017: cempra achieves the primary endpoint of a 10% non-inferiority margin. the microbiological success in each me population with methicillin-resistant s. aureus (mrsa) infection is 100 percent (99/99) at both the eot and pte visits. (2017)